Phase 3 Randomized, Double-Blind, Controlled Study of ICT-107 in Glioblastoma

Investigator: David Baskin, MD

Study Coordinator: Julie Baskin

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT02546102

Phone: 713.441.3800

IRB Number: Pro00013739

Description

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to evaluate ICT-107 in patients with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target glioblastoma tumour cells.
More to Explore